Clinical trials: Ejection Fraction
Heart Failure, Healthy Volunteer
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
- Trial name
- NCT03276728
- Testing
- AMG 986 IV, AMG 986 PO
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Amgen
Heart Failure With Preserved Ejection Fraction
HEART Camp Connect: A Feasibility Study
This study builds on the tested and refined HEART Camp intervention which has been shown to improve long-term adherence to exercise in individuals diagnosed with heart failure.
- Trial name
- NCT05985395
- Testing
- HEART Camp Connect
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Heart Failure, Diastolic
CoQ10 and D-ribose in Patients With Diastolic Heart Failure
The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).
- Trial name
- NCT03133793
- Testing
- CoQ10, D-Ribose Oral Powder
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Chronic Heart Failure With Reduced Ejection Fraction
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
The purpose of this randomized, actively controlled, double-blind study with prospective data collection was to assess differences between sacubitril/valsartan versus enalapril in increasing exercise capacity and non-sedentary…
- Trial name
- OUTSTEP-HF (NCT02900378)
- Testing
- LCZ696 (Sacubitril/Valsartan), Enalapril
- Where
- 119 sites in Belgium, Bulgaria and 17 more
- Volunteers
- 621 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy
Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying
This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying.
- Trial name
- NCT00685477
- Testing
- Experimental Sequence ABC, Experimental Sequence ACB, Experimental Sequence BAC
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Temple University
Heart Failure, Diastolic
External Body Pressure in Heart Failure With Preserved Ejection Fraction
The primary objective of the study is to test the impact of positive and negative body pressure on exercise capacity, symptoms, blood volume distribution and central cardiac hemodynamics in patients with heart failure and…
- Trial name
- NCT05764564
- Testing
- Positive or negative pressure
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Duke University
Heart Failure
Chronotropic Incompetence in Patients With HFpEF
The purpose of this study is to determine the mechanisms of chronotropic incompetence (inability to increase heart rate with exercise) in patients with heart failure and preserved ejection fraction (HFpEF).
- Trial name
- NCT02524145
- Testing
- Static Handgrip, Dexmedetomidine, Glycopyrrolate
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cardiac Disease
PROSPECTIVE EVALUATION OF HEARTFOCUS
The study's objective is to evaluate if exams, performed with the HeartFocus software by novices, are of sufficient quality to visually analyze the left ventricular size, the left ventricular function, the right ventricular size…
- Trial name
- HF-01 (NCT05874128)
- Testing
- Using HeartFocus software with AI guidance (Novices), Using HeartFocus software without AI-guidance
- Where
- 2 sites in United States, France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- DESKi
Diabetes Mellitus, Type 2
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
Albiglutide, a novel analogue of glucagon-like peptide-1 (GLP-1), has been developed and approved for the treatment of type 2 diabetes mellitus.
- Trial name
- NCT02496221
- Testing
- Albiglutide 50 mg, CCK (Kinevac)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline